Hyloris Bolsters Management Team Following Approvals
Appoints COO Following Maxigesic IV Nods In Eight European Countries
Belgian value-added medicines specialist Hyloris Pharmaceuticals has bolstered its management team with the appointment of a chief operating officer, shortly after receiving eight European approvals for its Maxigesic IV pain treatment.
You may also be interested in...
Hyloris Rolls Out Maxigesic IV In Europe
Hyloris has launched its Maxigesic IV value-added medicine in Germany and Austria, taking to five its total number of commercialized markets for the non-opioid intravenous analgesic.
Hyloris Sets Out Plans To Expand Its Pipeline
After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024.
Hyloris Adds Aguettant Deals For Maxigesic IV In Europe
Hyloris has secured licensing deals with Aguettant for its Maxigesic IV combination of paracetamol and ibuprofen in a further eight European markets through partner AFT Pharmaceuticals.